Tarsus Pharamceuticals

Manager II, Clinical Trials

Irvine, California, United States

$60,000 – $80,000Compensation
Mid-level (3 to 4 years), Senior (5 to 8 years)Experience Level
Full TimeJob Type
UnknownVisa
Pharmaceuticals, Clinical Research, BiotechIndustries

Requirements

Candidates should possess a Bachelor’s degree in a life science field, a minimum of 8 years of clinical research experience at a Pharmaceutical, Biotech, or CRO company with global proficiency, at least 2 years of experience as a clinical trial manager in the eyecare industry, and a minimum of 2 years of vendor management experience including CROs and labs. Additionally, one year of site monitoring experience, including qualification, initiation, and monitoring, is required.

Responsibilities

The Manager II, Clinical Trials will oversee and manage key study activities such as study start-up, development of study plans, vendor management, drug inventory, lab supplies, and sample management, while also reviewing protocols, CRFs, and other study documents. They will participate in user acceptance testing, develop training materials and site study materials, assist in site qualification, ensure study staff are properly trained, arrange and oversee site visits, provide Sponsor oversight of monitoring activities, organize presentations, manage drug supply inventory, review study budgets, assist in creating project tools, review Clinical Study Reports, and serve as a resource for others within the company. Furthermore, the role involves developing study timelines, managing study finances and forecasting, and working cross-functionally to report on study status and strategy.

Skills

Protocol Development
CRF Development
Vendor Management
CRO Management
Site Monitoring
Study Start-up
Budget Management
Clinical Study Reporting
Training Material Development
Project Management

Tarsus Pharamceuticals

Develops treatments for eye care diseases

About Tarsus Pharamceuticals

Tarsus Pharmaceuticals develops treatments for diseases that lack effective solutions, focusing mainly on eye care and infectious diseases. Their key product, XDEMVY, is an FDA-approved eye drop solution used to treat Demodex Blepharitis, a condition affecting the eyelids. The company is also working on other potential treatments for conditions such as Lyme Disease Prevention, Meibomian Gland Disease, and Rosacea. Tarsus differentiates itself from competitors by concentrating on specific medical needs and maintaining a strong pipeline of future products. Their goal is to provide effective treatments for patients suffering from these conditions while ensuring compliance with regulations and ethical standards.

Key Metrics

Irvine, CaliforniaHeadquarters
2017Year Founded
$58.4MTotal Funding
IPOCompany Stage
Biotechnology, HealthcareIndustries
201-500Employees

Benefits

Health Insurance
Dental Insurance
Vision Insurance
Paid Vacation
Hybrid Work Options
Professional Development Budget

Risks

Increased competition in ophthalmic treatments challenges Tarsus's market position.
Potential clinical trial delays could affect Tarsus's product pipeline.
Supply chain constraints may hinder XDEMVY's production and distribution.

Differentiation

Tarsus focuses on high unmet needs in ophthalmic and infectious diseases.
Their lead product, XDEMVY, is FDA-approved for Demodex blepharitis treatment.
Tarsus's pipeline includes innovative treatments for Lyme disease and Rosacea.

Upsides

Growing awareness of Demodex blepharitis expands market for Tarsus's XDEMVY.
Telemedicine rise offers new marketing opportunities for Tarsus's products.
FDA's focus on unmet needs may expedite Tarsus's pipeline approvals.

Land your dream remote job 3x faster with AI